Efficacy and Safety of TAS-303 in Female Patients With Stress Urinary Incontinence: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial

Overview of attention for article published in The Journal of Urology, August 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

So far, Altmetric has seen 23 news stories from 20 outlets.

(HealthDay News) — Once-daily TAS-303 is superior to placebo for treatment of stress urinary incontinence (SUI) in women…

TUESDAY, July 30, 2024 -- Once-daily TAS-303 is superior to placebo for treatment of stress urinary incontinence (SUI) in women…

(HealthDay News) — Once-daily TAS-303 is superior to placebo for treatment of stress urinary incontinence (SUI) in women…

TUESDAY, July 30, 2024 (HealthDay News) -- Once-daily TAS-303 is superior to placebo for treatment of stress urinary…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 19 additional news stories.